Asia-Pacific consensus on gastroesophageal reflux disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue 4, 2004, Pages 353-356

  Wong, Wai Man ^a,b   Hui, Wai Mo ^a   Wong, Benjamin Chun Yu ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

ANTIREFLUX OPERATION; ASIA; ATROPHIC GASTRITIS; BARRETT ESOPHAGUS; BURNING SENSATION; CONSENSUS; DRUG SAFETY; EDITORIAL; ENDOSCOPY; EPIDEMIOLOGICAL DATA; ERADICATION THERAPY; GASTROESOPHAGEAL REFLUX; HEARTBURN; HELICOBACTER PYLORI; HUMAN; MAINTENANCE THERAPY; PATHOGENESIS; PEPTIC ULCER; PH; PREVALENCE; PRIORITY JOURNAL; QUESTIONNAIRE; RADIOFREQUENCY;

EID: 2342453814     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03432.x     Document Type: Editorial

References (56)

1. Locke GR 3rd, Talley NJ, Fett SL et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56.
2. Agreus L, Svardsudd K, Talley NJ et al. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population based study. Am. J. Gastroenterol. 2001; 96: 2905-14.
3. Holtmann G. Reflux disease: the disorder of the third millennium. Eur. J. Gastroenterol. Hepatol 2001; 13 (Suppl.): S5-11.
4. Haque M, Wyeth JW, Stace NH et al. Prevalence, severity and associated features of gastro-oesophageal reflux and dyspepsia: a population-based study. NZ Med. J. 2000; 113: 178-81.
5. Stanghellini V. Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic/ International Gastroenterology Surveillance Study (DIGEST). Scand. J. Gastroenterol. 1999; 231 (Suppl.): 20-8.
6. Isolauri J, Laippala P. Prevalence of symptoms suggestive of gastro-oesophageal reflux disease in an adult population. Ann. Med. 1995; 27: 67-70.
7. Ruth M, Mansson I, Sandberg N. The prevalence of symptoms suggestive of esophageal disorders. Scand. J. Gastroenterol. 1991; 26: 73-81.
8. Jones RH, Lydeard SE, Hobbs FD et al. Dyspepsia in England and Scotland. Gut 1990; 31: 401-5.
9. Frank L, Kleinman L, Ganoczy D et al. Upper gastrointestinal symptoms in North America: prevalence and relationship to healthcare utilisation and quality of life. Dig. Dis. Sci. 2000; 45: 809-18.
10. Kennedy T, Jones R. The prevalence of gastrooesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment. Pharmacol. Ther. 2000; 14: 1589-94.
11. Louis E, DeLooze D, Deprez P et al. Heartburn in Belgium: prevalence, impact on daily life, and utilisation of medical resources. Eur. J. Gastroenterol. Hepatol. 2002; 14: 279-84.
12. Dent J, Brun J, Fendrick AM et al. An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 1999; 44 (Suppl. 2): S1-16.
13. Sandler RS, Everhart JE, Donowitz M et al. The burden of selected digestive diseases in the Unites States. Gastroenterology 2002; 122: 1500-11.
14. DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Arch. Intern. Med. 1995; 155: 2165-73.
15. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am. J. Gastroenterol. 1999; 94: 1434-42.
16. The 1996 Canadian outlook on gastroesophageal reflux disease. Consensus Conference. Ottawa, Ontario, June 1996. Can. J. Gastroenterol. 1997; 11 (Suppl. B): 1-112B.
17. The Second Canadian Consensus Conference on the Management of Patients with Gastroesophageal Reflux Disease. Can. J. Gastroenterol. 1997; 11 (Suppl. B): 7-20B.
18. Baldi F, Crotta S, Penagini R. Guidelines for the diagnostic and therapeutic management of patients with gastro-oesophageal reflux disease. A position statement of The Italian Association of Hospital Gastroenterologists (AIGO), Italian Society of Gastrointestinal Endoscopy (SIED), and Italian Society of Gastroenterology (SIGE). Ital. J. Gastroenterol. Hepatol. 1998; 30: 107-12.
19. French-Belgian Consensus Conference on Adult Gastrooesophageal Reflux Disease. 'Diagnosis and Treatment': report of a meeting held in Paris, France, on 21-22 January 1999. The jury of the consensus conference. Eur. J. Gastroenterol. Hepatol. 2000; 12: 129-37.
20. Uscanga L, Nogueira-d, e-Rojas JR et al. Gastroesophageal reflux disease. Gastroenterology Mexican Association consensus. Mexican group for the GERD study. Rev. Gastroenterol. Mex. 2002; 67: 216-23.
21. Moraes-Filho J, Cecconello I, Gama-Rodrigues J et al. Brazilian consensus on gastroesophageal reflux disease, proposals for assessment, classification, and management. Am. J. Gastroenterol. 2002; 97: 241-8.
22. Tytgat GN, Heading RC, Muller-Lissner S et al. Contemporary understanding and management of reflux and constipation in the general population and pregnancy: a consensus meeting. Aliment. Pharmacol. Ther. 2003; 18: 291-301.
23. Moss SF, Armstrong D, Arnold R et al. GERD 2003 - a consensus on the way ahead. Digestion 2003; 67: 111-17.
24. Fock KM, Talley N, Hunt R et al. Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease. J. Gastroenterol. Hepatol. 2004; 19; 357-367.
25. Ho KY, Kang JY, Seow A. Prevalence of gastrointestinal symptoms in a multiracial Asian population, with particular reference to reflux-type symptoms. Am. J. Gastroenterol. 1998; 93: 1816-22.
26. Goh KL, Chang CS, Fock KM et al. Gastro-oesophageal reflux disease in Asia. J. Gastroenterol. Hepatol. 2000; 15: 230-8.
27. Wong WM, Lai KC, Lam KF et al. Prevalence, clinical spectrum and health care utilisation of gastro-oesophageal reflux disease in Chinese population: a population-based study. Aliment. Pharmacol. Ther. 2003; 18: 595-604.
28. Kang JY, Tay HH, Yap I, Guan R, Lim KP, Math MV. Low frequency of endoscopic esophagitis in Asian patients. J. Clin. Gastroenterol. 1993; 16: 70-3.
29. Chang CS, Poon SK, Lien HC, Chen GH. The incidence of reflux esophagitis among the Chinese. Am. J. Gastroenterol. 1997; 92: 668-71.
30. Yeom JS, Park HJ, Cho JS, Lee SI, Park IS. Reflux esophagitis and its relationship to hiatal hernia. J. Korean Med. Sci. 1999; 14: 253-6.
31. Wong WM, Lam SK, Hui WM et al. Long-term prospective follow-up of endoscopic oesophagitis in southern Chinese - prevalence and spectrum of the disease. Aliment. Pharmacol. Ther. 2002; 16: 2037-42.
32. Locke GR, Talley NJ, Weaver AL, Zinsmeister AR. A new questionnaire for gastroesophageal reflux disease. Mayo Clin. Proc. 1994; 69: 539-47.
33. Carlsson R, Dent J, Bolling-Sternevald E et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand. J. Gastroenterol. 1998; 33: 1023-9.
34. Wong WM, Lam KF, Lai KC et al. Validated symptoms questionnaire (Chinese-GERDQ) for the diagnosis of gastro-oesophageal reflux disease in Chinese population. Aliment. Pharmacol. Ther. 2003; 17: 1407-14.
35. Spechler SJ, Jain SK, Tendler DA, Parker RA. Racial differences in the frequency of symptoms and complications of gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 2002; 16: 1795-800.
36. Spechler SJ. Clinical practice. Barrett's esophagus. N. Engl. J. Med. 2002; 346: 836-12.
37. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment. Pharmacol. Ther. 2003; 17: 537-45.
38. Fass R, Ofman JJ, Gralnek IM et al. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch. Intern. Med. 1999; 159: 2161-8.
39. Fass R, Fennerty MB, Ofman JJ et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 1998; 115: 42-9.
40. Xia HHX, Lai KC, Lam SK et al. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. Aliment. Pharmacol. Ther. 2003; 17: 369-7.
41. Juul-Hansen P, Rydning A, Jacobsen CD, Hansen T. High-dose proton-pump inhibitors as a diagnostic test of gastro-oesophageal reflux disease in endoscopic-negative patients. Scand. J. Gastroenterol. 2001; 36: 806-10.
42. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
43. Vigneri S, Termini R, Leandro G et al. A comparison of five maintenance therapies for reflux esophagitis. N. Engl. J. Med. 1995; 333: 1106-10.
44. Lind T, Havelund T, Lundell L et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment. Pharmacol. Ther. 1999; 13: 907-14.
45. Talley NJ, Lauritsen K, Tunturi-Hihnala H et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment. Pharmacol. Ther. 2001; 15: 347-54.
46. Talley NJ, Venables TL, Green JR et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur. J. Gastroenterol. Hepatol. 2002; 14: 857-63.
47. Varanasi RV, Fantry GT, Wilson KT. Decreased prevalence of H. pylori infection in gastroesophageal reflux disease. Helicobacter 1998; 3: 188-94.
48. Koike T, Ohara S, Sekine H et al. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut 2001; 1: 330-4.
49. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112: 1442-7.
50. Schwizer W, Thumshirn M, Dent J et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 2001; 357: 1738-42.
51. Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001; 121: 1120-6.
52. Laine L, Sugg J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am. J. Gastroenterol. 2002; 97: 2992-7.
53. Kuipers EJ, Lundell L, Klinkenberg-Knol EC et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N. Engl. J. Med. 1996; 334: 1018-22.
54. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment. Pharmacol. Ther. 2002; 16: 167-80.
55. Spechler SJ, Lee E, Ahnen D et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001; 285: 2331-8.
56. Fennerty MB. Endoscopic therapy for gastroesophageal reflux disease, what have we learned and what needs to be done? Gastrointest. Endosc. Clin. N. Am. 2003; 13: 201-9.